Ã山ǿ¼é

This workshop is organized by Dr. Pedro Rosa-Neto, MD, PhD, from The Douglas Research Centre, Ã山ǿ¼é, and The Neuro. The event will focus on discussing the indications, prescription, and management of adverse events associated with anti-amyloid therapy using monoclonal antibodies.

The workshop will provide valuable insights into the latest treatment strategies and guidelines, aiming to equip healthcare researchers and professionals with the necessary tools to manage and prescribe anti-amyloid therapies effectively. Additionally, it will help enhance the knowledge and skills required to handle adverse effects associated with these treatments.

For virtual attendance,

Suzanne Schindler, MD, PhD

Department of Neurology, Washington University School of Medicine

°Õ²¹±ô°ì:ÌýDiagnosis and Treatment of EarlyÌý Symptomatic Alzheimer’s Disease

Abstract: The early and accurate diagnosis of Alzheimer’s disease in patients with cognitive impairment is more important than ever now that disease-modifying treatments are becoming available. This lecture will describe how to diagnose early symptomatic Alzheimer’s disease by integrating clinical information with biomarker tests. The advantages and disadvantages of amyloid PET, CSF biomarkers, and new blood biomarkers will be reviewed with a focus on clinical blood biomarker tests. Further, the identification, treatment, and monitoring of appropriate patients for anti-amyloid treatments will be discussed. Real-world data and experience with biomarker testing and anti-amyloid treatments from the Washington University Memory Diagnostic Center will be detailed.

Alireza Atri, MD, PhD

Department of Neurology, Harvard Medical School

°Õ²¹±ô°ì:ÌýAmyloid Related Imaging Abnormalities (ARIA)

Abstract: TBD

Ìý